Skip to Main Content

In the latest dust-up over the safety of medicines, the European Medicines Agency recommended suspending marketing authorization for dozens of generic drugs after finding problems with tests conducted by a contract research organization.

Specifically, the regulator pointed to “serious concerns” about the quality and reliability of data in bioequivalence studies run by Synchron Research Services, which is based in Ahmedabad, India. Bioequivalence studies are conducted to show that a generic medicine releases the same amount of an active ingredient in the body as a brand-name medicine.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment